A multifunctionalized nanodevice based on natural hyperbranched glycogen nanoparticles had been fabricated for tumor therapy. Glycogen nanoparticles were decorated with liver cancer cell-targeted agent β-galactose and anticancer drug doxorubicin via schiff-base reaction. It was found that the glycogen nanocarrier could be taken by liver cancer cell selectively owing to galactose-ASGPR binding. After endocytosis, drug could be released from nanoparticles due to the cleavage of hydrazone-based bond at acidic tumor cell environment. The in vivo study demonstrated that this glycogen based drug delivery system minimized uptake and drug leakage in normal organs, enhanced accumulation and efficient drug release at tumor sites, inhibiting tumor growth with only slight retention in normal liver tissues. This strategy on exploiting glycogen nanoparticles as anticancer drug vehicle provides alternative platform for on-demand and targeted cancer therapy.

基于天然超支化糖原纳米粒子的多功能纳米设备已被制成用于肿瘤治疗。通过席夫碱反应，用肝癌细胞靶向剂β-半乳糖和抗癌药阿霉素修饰糖原纳米颗粒。已经发现由于半乳糖-ASGPR的结合，肝癌细胞可以选择性地摄取糖原纳米载体。内吞后，由于基键在酸性肿瘤细胞环境中的裂解，药物可从纳米颗粒中释放出来。在体内研究表明，这种基于糖原的药物递送系统可最大程度地减少正常器官的吸收和药物泄漏，增强肿瘤部位的积累和有效的药物释放，从而抑制肿瘤的生长，仅保留在正常肝组织中。利用糖原纳米颗粒作为抗癌药物载体的这一策略为按需和靶向癌症治疗提供了替代平台。